Peiptídí a chuireann dul chun cinn ar aghaidh.
Rogha na dtaighdeoirí.
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%Lookbook.
Ceithre roinn.
Gach comhdhúil, doiciméadaithe.
Gan buidéal gan ainm riamh.
Seoltar gach táirge lena chárta Peptheon — céannacht, foirm agus aicme na comhdhúile ar an toirt, chomh maith le tástáil saotharlainne, doiciméadú baisce agus seachadadh discréideach inrianaithe mar chaighdeán.
Ón deasc taighde.
BioregulatorsCartalax and Chonluten: the bioregulators with almost no published record
Same Khavinson school as Thymalin and Epithalon, a fraction of the evidence. One cell-culture study for Chonluten, no readable efficacy study at all for Cartalax — and that asymmetry is the article.
LongevityEpithalon and the telomere claim: what the Khavinson papers actually report
Telomerase reactivation in a dish, extra passages past the Hayflick limit, longer-lived flies and mice — and no modern human trial. The published Epithalon record, figure by figure.
PerformanceMyostatin inhibitors: ACE-083 went to phase 2, follistatin-344 never left the lab
One follistatin-based molecule grew muscle in two randomised phase 2 trials and still failed where it mattered. The other has only animal data, a black market, and a retinal case series. The published record, side by side.